Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BW
One thing was right today and that was the PPS, We broke through the 10 wall fairly well even if it did not close there.
BTH
I dont recall saying this but I did expect something different going into and during ASCO? We had the bear raid and the big seller afterwards. I expected this to trade sideways after ASCO. I was unaware of the I.I . meeting on Friday when this statement was made. Does anyone know when the PR on last Fridays meeting was released? Just trying to gauge if the Harv was unhappy with the action during ASCO and then decided to hold the Int. investors meeting? We all know dilution is possible is why I watch the Harvs moves.
Wasn't there a mention of Ariad being "tired" recently?
Thats the way to do it. Take some profits early and hedge your bet, especially when dealing with the FDA. If I could, I would go into any FDA decision riding free shares every time. Not always possible.
BW
I don’t recall the company mentioning anything about a 4th compound. I think it was pure speculation at the board due to Ariad becoming a standalone company and a drug pipeline. Please correct me if I’m wrong.
ARIA hitting new highs today+.83
Ya think some of those at the meeting Friday are buying.I wonder how many of those Short attended? LOL This has got to be the best day ARIA has had in 12 months.
"I have some non-biotech hedges in place that hopefully will protect me in that case. I generally maintain a short position in the overall market to partially hedge my long positions in biotech and some other sectors. "
Peter
It appears that you agree with BTH from what you stated in your post?
I feel we all should be aware of the MACRO environment at this time! It could collapse again, just s fast as it has in the past.
Seeking Alpha No More
Amazing these 2 recent articles came from the same site? I think you and I could get the same creditbility in the public Eye. We could name it EYE BUY STOX ON DIPS.
Seeking Alpha is losing credibility with the public IMO. This article is just a cover there ass from the last inept article.
I suspect less and less people will give any creditability to SA in the future. I consider them just above SPAM at this point. I wonder if the SEC has contacted them at this point in time. I think they will.
Thanks for posting.
BoD
I feel when you copy and past anothers post you should copy the entire post. You omitted the last lines of Sheffs post.
Disclaimer: This is not a recommendation to buy or sell this security. This is my personal opinion. Please do your own DD on any stock mentioned on this board.
I'm long FCSC but I suggest you copy the link next time! This will prevent any TYPOS.
LINK: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64367157
Congrats 2dm and BW
In the May poll the majority of votes pointed to dilution in the second half of 2011. At what price do you think ARIA will have dilution to fund the upcoming drugs? It seemed the PPS recovered quite fast on the last one.
You are correct and I agree, The Key word in your post was SUGGEST AKA speculation :Charts, they graph history. They dont fortell the future. I use them as a tool; nothing more.
ChemGenex Pharmaceuticals
OMAPRO™ (omacetaxine mepesuccinate) ODAC Briefing Book
7
Point mutations in the Abl kinase domain of Bcr-Abl are the most commonly reported cause
of imatinib resistance, representing 50 to 80% of patients with imatinib failure. Point
mutations lead to amino acid substitutions that interfere with binding of imatinib. The second
generation compounds, dasatinib and nilotinib, have increased binding affinity to the Abl
kinase domain over imatinib and subsequently have activity against many of the imatinibresistant
kinase domain mutants. None, however, are effective against one particular
mutation, T315I.
1.3 The Medical Need of the CML T315I Patient
All TKI-treated CML patients will become resistant to further TKI therapy if they develop
the specific Bcr-Abl kinase domain mutation, T315I. Replacement of threonine with
isoleucine at position 315 (T315I) in the Abl kinase domain blocks the binding of all three
approved TKIs to the ATP-binding site and leads to drug resistance. Treatment of CML
patients with the T315I mutation by any of these TKI then leads to selection of the resistant
CML cells, and an increasing proportion of the total burden of CML cells will contain the
T315I mutation.
An estimated 250 to 300 CML patients are diagnosed with the T315I mutation per year in the
US, and the incidence is expected to increase as dasatinib and nilotinib are more widely used.
The presence of the T315I mutation has been associated with a poor prognosis. In contrast to
the 10 year survival for patients with CML-CP treated with imatinib, the patient with the
T315I mutation has a survival of 22 months from the time the mutation is detected.
With the exception of stem cell transplantation, there are currently no effective therapies for
CML with the T315I mutation. Patients unsuitable for transplantation are managed with
agents such as hydroxyurea (HU) that provide supportive care but do not prolong survival.
As such, CML patients with the T315I mutation have a poor prognosis and an unmet medical
need which requires a proven therapy.
1.4 Product Rationale
Omacetaxine is a reversible protein translation inhibitor that is active against Mcl-1, an
important regulator of lymphocytic and hematopoietic stem cell survival, leading to apoptosis
in leukemic cell lines. Unlike the TKIs, omacetaxine does not depend on Bcr-Abl binding for
I felt compelled to comment here. Charts are a graph of HISTORY. They can be used for speculation of future performance in trends. One PR can make any chart worthless. I use charts for what they are, a reference. Yes I’m long but I don’t buy into the whole chart mantra!
BTH
I for one feel BTH keeps this boards feet on the GROUND. He does upset the perma bulls sometimes, and at times calls this stock a PIG. I have no problem with that. It has been a PIG at times.
In the end BTH has stellar DD. He adds his research when he makes his call. Unlike some that see the stars for ARIA with no supporting facts.
BOD
PS
No, I'm not new to the board as one suspected in the PM I received. I entered ARIA in the 3's I just dont post as often as others, but I'm here every day and have been for some time now.
Rule #1 The Golden Rule. A great Attorney will want a substantial CASH RETAINER up front. I suspect this was part of MB's problem. I suspect many of his assets were frozen!
As far as the Gov holding MB and the others liable for the entire amount " Evo is out of country, they will hold the ones they have " in hand" responsible for his gains also." Even if they never get him. I think they already knew he was out of reach?
CONTACT INFORMATION
I think if many of us contacted these 2 individuals (maybe via e-mail if we can google their names), this would put this guy on the radar.
For more information about this enforcement action, contact:
Michael Paley
Assistant Regional Director, SEC’s New York Regional Office
(212) 336-0145
Elisha L. Frank
Assistant Regional Director, SEC’s Miami Regional Office
305) 982-6392
E-trade? I ask why you continue to deal with it. This is the second post today about this. FIRE THEIR ASS and find a broker that will. Have you forgotten who the customer is?
Inv2win
"Tomorrow IMO should be a good indication of which direction it will take. Good Luck to everyone!(myself included) "
The results are solid. I will wait until Friday close to determine the direction. ASCO is behind us, but many will trade on that news until Monday.
I'm a buyer under 3.60 that breached 2 times today.
I for one consider the bet null and void. Bottom was aprox 7.89 and the top 9.58 ??? I call it a draw. I appeares no one hit the exact number.Imagine that. If its open ended for months thats up to them?
I would rather trade this stock. Pleanty of gains to be made. I have guessed wrong 3 times now since the 3s but it returns green each time if I wait.
Take a look SEC MOVES TODAY
http://www.sec.gov/news/press/2011/2011-120.htm
I understand. Another example could be the way Lasic Sugery was handeled when it hit the market I guess.
Kipperdo
FCSC has addressed these issues and plans to set a high bar for physicians going forward
How do they plan to accomplish this?
GOOD BUY
I thought it was going down a little futher when it broke 3.60 the second time!
With ASCO behind us, It will be interesting where we close on Friday. I think we trade sideways from there for a while.
Good for you, here comes your chance again: just droped below the 3.60.
I looks like they want to take it to -50% from 5.48 high.
Getting cheap shares so they can load up for the Russell addition
There will be no Russell addition at this PPS!
Hang on, from the looks of the chart you may be able to lower even futher.
The Ex CEO only planed to sell 1,500,000 thats not the problem here. Many are dumping this stock not just 1.
The Years of patient protection is not correct in the article.
You Beat me to it! BTH may not have hit the exact number, but he was very close so far.
BTH
The FDA will most likely approve the drug bc they met the SPA. But one must realize that in the end, this is no milestone ! I classify this drug like a Band-Aid on a Bullet Hole. Give that some thought. Gov/ Insurance companies are not going to pay for this very long imo. I reference this to the NICE article of late. I feel this is could be nothing more than a fleecing of the public that is willing to pay for it. And some will hang on to every moment of life. I do think this is where the medical business takes advantage of people.
Business is what it is today; I don’t think these were these were the intentions from the start?
Any thoughts?
I agree the next few days will be interesting to say the least. I honestly expect to be underwhelmed with the ASCO presentation. I feel the news was out on the abstract, less an iota.
As far a Rida I’m not impressed. I even tried to place myself in this situation. 30 days > Hell even 60-90 days?
I own this stock. If I were on the FDA panel I could not approve the NDA with these types of results. I think they may, but I don’t see any significant gain for the patient. I do see a huge loss of capitol for their dependents they leave behind.
If I ruffled some feathers here fine. I call them like I see them.
Here is the 1 June 2011 8K SEC filing.
http://sec.gov/Archives/edgar/data/810509/000114420411033376/v224681_8k.htm
I still think LaViv will get approved. I have to wait 3 weeks for my gains now, not 3 days.
I agree
BTH Great article
Thanks for sharing.
I agree especially with this statement and extend it to any politicians in office regardless of party.
OrbiMed, our Investment Manager, believes that the outlook for the healthcare
sector is good although volatility in the sector may increase if the
Republicans decide to reform the current U.S. healthcare bill.,
This is my opinion only from the closing trades and volume. I have no information to confirm this.
I’m not concerned with an insider trade of 80K when trades of 2.26 mil show at the close with 3x volume. This stock finally starting to make a move with volume. A Fund invested today imo.
Take a look at the closing trade prints.
OPTR 14.21 Congrats to those holding :
Optimer Pharmaceuticals (OPTR) NewsBite - OPTR Rises 6.5% on US Dificid Approval
2 hours 41 minutes ago - FreshBrewedMedia
Optimer Pharmaceuticals (NASDAQ: OPTR) opened at $13.70. So far today, the stock has hit a low of $13.60 and a high of $14.25. OPTR is now trading at $13.83, up $0.85 (6.51%). Over the last 52 weeks the stock has ranged from a low of $7.68 to a high of $14.70. OPTR shares are on the move after the company won approval to market its drug Dificid for hospital infections in the US. Technical indicators for the stock are bullish and S&P does not currently have a STARS rating for OPTR. If you are looking for a hedged play on OPTR the stock seems like it could be a candidate for a July out-of-the-money bull-put credit spread below the 12.50 range.
I hope it will POP. I think we will know more, as the info comes out? I look forward to the ASCO presentation? I need something substantial to hold, this stock has not preformened to date. I have my doubts. I will wait and see for the moment.
-------------------------------------------------------------------
Well, we know we will receive a pop in share price upon NDA filing of Rida, and an even BIGGER pop on approval of Rida"?? Unknown" by the FDA. Could be a great exit point if you don't want to wait for Pona..
------------------------------------------------------------------
More like a Great trade opportunity than anything else to me.
I also feel there will be another sell off after ASCO. I have taken advantage of the 2 prior. I was expecting the Bear Raid but not the disgorging of 2+ million shares a couple days later by a single fund. They completely controlled the trades that day. I was expecting that after ASCO over a couple of days but deeper.
KF